المصدر: Barrons
وكالة أنباء
عام
أهمية متوسطة
EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.
Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.
المصدر: Barrons
زيارة المصدر